Beta
ManageSearchChatDiscover
271774

PREVALENCE OF CYP2D6*4 AND ITS POSSIBLE RELATION TO THERAPEUTIC OUTCOMES OF ADJUVANT TAMOXIFEN THERAPY IN EGYPTIAN PREMENOPAUSAL WOMEN WITH BREAST CANCER

Article

Last updated: 04 Jan 2025

OverviewSimilar Items

Subjects

-

Tags

-

Abstract

Background: Although tamoxifen is a main adjuvant therapy in estrogen positive breast cancer especially in premenopausal women, reliance on genetic polymorphisms of its CYP2D6 metabolizing enzyme and/or therapeutic drug monitoring of its active metabolite, endoxifen to determine tamoxifen-therapeutic outcomes is debatable. Objective: The goal of the study was to investigate the prevalence of CYP2D6*4 and possible association between its nonfunctional allele (A) and both tamoxifen-induced adverse effects and cancer relapse in premenopausal breast cancer patients. Method:Polymerase chain reaction -restriction fragment length polymorphism (PCR-RFLP) analysis was applied for detection of CYP2D6*4 (1846 G>A) genotypes. Results:Genotyping analysis of CYP2D6*4 showed a minimal allele frequency of 23%. Increased endometrial thickness in mm was significantly correlated with CYP2D6*4 GA and AA genotypes in comparison with GG genotypes (P< 0.01). No other relations were found between CYP2D6*4 alleles and other tamoxifen adverse effects (P > 0.9) or cancer relapse (P= 0.7). Conclusion: The prevalence of CYP2D6*4 polymorphism in Egyptian premenopausal females with breast cancer who are given tamoxifen is similar to that in Caucasians. The nonfunctional allele (A-allele) of CYP2D6*4 showed a significant association with increased endometrial thickness possibly related to tamoxifen, but no association with other drug adverse effects or cancer relapse.
          

DOI

10.21608/bfsa.2022.271774

Keywords

tamoxifen, CYP2D6*4, premenopausal Egyptian females, breast cancer

Authors

First Name

Mohammad

Last Name

Hareedy

MiddleName

Salem

Affiliation

Department of Pharmacology, Faculty of Medicine, Assiut University, Egypt.

Email

dr_mohamadsalem@yahoo.com

City

-

Orcid

-

First Name

Amira

Last Name

Taha

MiddleName

F.

Affiliation

Department of Pharmacology and Toxicology, Faculty of Pharmacy, Assiut University, Egypt.

Email

dr_amira.fawzy88@hotmail.com

City

-

Orcid

-

First Name

Abeer

Last Name

Ibrahim

MiddleName

-

Affiliation

Department of Medical Oncology and Hematological Malignancy, South Egypt Cancer Institute, Assiut University, Egypt.

Email

ab_elsayed2003@yahoo.com

City

-

Orcid

-

First Name

Medhat

Last Name

Saleh

MiddleName

A.

Affiliation

Department of Public Health and Community Medicine, Assiut University, Egypt.

Email

medhataraby75@gmail.com

City

-

Orcid

-

First Name

Mohamed

Last Name

Abdelrady

MiddleName

A.

Affiliation

Faculty of Medicine, Assiut University, Egypt.

Email

mohamedradybalela@hotmail.com

City

-

Orcid

-

First Name

Ehab

Last Name

EL Desoky

MiddleName

S.

Affiliation

Department of Pharmacology, Faculty of Medicine, Assiut University, Egypt.

Email

-

City

-

Orcid

-

Volume

45

Article Issue

2

Related Issue

37882

Issue Date

2022-12-01

Receive Date

2022-03-23

Publish Date

2022-12-01

Page Start

935

Page End

951

Print ISSN

1110-0052

Online ISSN

3009-7703

Article File

BFSA_Volume 45_Issue 2_Pages 935-951.pdf

PDF . 1.2MB

Link

https://bpsa.journals.ekb.eg/article_271774.html

Detail API

https://bpsa.journals.ekb.eg/service?article_code=271774

Order

271,774

Type

Original Article

Type Code

1,096

Publication Type

Journal

Publication Title

Bulletin of Pharmaceutical Sciences Assiut University

Publication Link

https://bpsa.journals.ekb.eg/

MainTitle

PREVALENCE OF CYP2D6*4 AND ITS POSSIBLE RELATION TO THERAPEUTIC OUTCOMES OF ADJUVANT TAMOXIFEN THERAPY IN EGYPTIAN PREMENOPAUSAL WOMEN WITH BREAST CANCER

Details

Type

Article

Created At

22 Jan 2023